Education
About Us
Working with TipRanks
Follow Us
Eugene Schneider Insider Profile
4 Followers
Eugene Schneider, EVP, Chf Clinical Develop Ofcr at Ionis Pharmaceuticals, holds 51.51K shares in Ionis Pharmaceuticals (Ticker: IONS).
Eugene Schneider Ionis Pharmaceuticals (IONS)EVP, Chf Clinical Develop Ofcr
Ionis Pharmaceuticals (IONS)
EVP, Chf Clinical Develop Ofcr
Ranked #42,039 out of 102,830 Corporate Insiders
Profitable Transactions
2 out of 4 Profitable Transactions
Average Return
+3.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Eugene Schneider's holdings
Insider Roles
EVP, Chf Clinical Develop Ofcr
Roles that Eugene Schneider holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Jan 17, 2024 - Jan 17, 2025
Return:+38.70%
The most profitable trade made by Eugene Schneider
Eugene Schneider's Trading History
List of latest transactions for each holding click on a transaction to see Eugene Schneider's performance on stock
You May Also Like
Eugene Schneider insider profile FAQ
What is the percentage of profitable transactions made by Eugene Schneider?
The percentage of profitable transactions made by Eugene Schneider is 50%.
What is the average return per transaction made by Eugene Schneider?
The average return per transaction made by Eugene Schneider is 3.10%.
What stocks does Eugene Schneider hold?
Eugene Schneider holds: IONS stocks.
What was Eugene Schneider’s latest transaction?
Eugene Schneider latest transaction was an Uninformative Sell of $408.70K.
What was Eugene Schneider's most profitable transaction?
Eugene Schneider’s most profitable transaction was an Informative Sell of IONS stock on January 17, 2024. The return on the trade was 38.70%.
What is Eugene Schneider's role in Ionis Pharmaceuticals?
Eugene Schneider's role in Ionis Pharmaceuticals is EVP, Chf Clinical Develop Ofcr.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.